A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Active, not recruiting · NCT06163326 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | Skin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligo | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06163326 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Pfizer | 431 |
73 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.